Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crism TherapeuticsAMMCF 35 Days Sales Outstanding is 418.16 as of Dec. 2025, which is 139% above its 10-year median of 175.20. GuruFocus rates AMMCF with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 840 Biotechnology companies, Crism Therapeutics ranks worse than 96.19% on this metric.
Crism Therapeutics (OTCPK:AMMCF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Crism Therapeutics Days Sales Outstanding Related Terms
Crism Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Crism Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMMCF vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Crism Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crism Therapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crism Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Crism Therapeutics's Days Sales Outstanding falls into.
Crism Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 418.16 mean?
Crism Therapeutics (AMMCF) has a Days Sales Outstanding of 418.16 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Crism Therapeutics and its competitors. This is 139% above median its historical median of 175.20. Over the past decade, Crism Therapeutics' Days Sales Outstanding has ranged from 97.33 to 835.87. According to the industry distribution chart, Crism Therapeutics ranks #808 out of 840 companies in the Biotechnology industry, placing it in the top 96.2%.
Is Crism Therapeutics' Days Sales Outstanding too high?
Crism Therapeutics' current Days Sales Outstanding of 418.16 is 139% above median its 10-year median of 175.20. Over the past 10 years, this metric has ranged from a low of 97.33 to a high of 835.87. The Biotechnology industry median Days Sales Outstanding is 69.09. Crism Therapeutics' value of 418.16 is 505.2% above this industry median. Based on the distribution chart, Crism Therapeutics ranks #808 out of 840 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crism Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Crism Therapeutics' Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Crism Therapeutics ranks #808 out of 840 companies for Days Sales Outstanding. This places Crism Therapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 69.09. Crism Therapeutics' value of 418.16 is 505.2% above this benchmark. Historically, Crism Therapeutics' own Days Sales Outstanding has ranged from 97.33 to 835.87 over the past decade. While the company's 10-year median is 175.20 vs. the industry median of 69.09, Crism Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.09, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crism Therapeutics's current Days Sales Outstanding of 418.16 is 505.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Crism Therapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crism Therapeutics's current Days Sales Outstanding is 418.16, which is 139% above median its own 10-year median of 175.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (AMMCF) has a current Days Sales Outstanding of 418.16. The current Days Sales Outstanding is 418.16, which is 139% above median its 10-year median of 175.20 and 505.2% above the Biotechnology industry median of 69.09. Crism Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Crism Therapeutics (AMMCF), the current Days Sales Outstanding is 418.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
35GF Score
Get the complete analysis for AMMCF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMMCF has been successfully added to your 
